Caveolins in rhabdomyosarcoma

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 12, 2011, Pages 2553-2568

  Rossi, Stefania ^a   Poliani, Pietro Luigi ^a   Missale, Cristina ^a   Monti, Eugenio ^a   Fanzani, Alessandro ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Caveolins; Rhabdomyosarcoma; Skeletal muscle

Indexed keywords

CAVEOLIN;

ARTICLE; CELL DIFFERENTIATION; HUMAN; METABOLISM; PATHOLOGY; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

CAVEOLINS; CELL DIFFERENTIATION; HUMANS; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

EID: 82455184960     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01364.x     Document Type: Article

References (230)

1. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev. 2002; 54: 431-67.
2. Williams TM, Lisanti MP. The caveolin proteins. Genome Biol. 2004; 5: 214.
3. Kurzchalia TV, Parton RG. Membrane microdomains and caveolae. Curr Opin Cell Biol. 1999; 11: 424-31.
4. Parton RG. Caveolae-from ultrastructure to molecular mechanisms. Nat Rev Mol Cell Biol. 2003; 4: 162-7.
5. Van Deurs B, Roepstorff K, et al. Caveolae: anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol. 2003; 13: 92-100.
6. Couet J, Li S, Okamoto T, et al. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem. 1997; 272: 6525-33.
7. Patel HH, Murray F, Insel PA. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxicol. 2008; 48: 359-91.
8. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol. 1961; 9: 493-5.
9. Le Grand F, Rudnicki MA. Skeletal muscle satellite cells and adult myogenesis. Curr Opin Cell Biol. 2007; 19: 628-33.
10. Volonte D, Liu Y, Galbiati F. The modulation of caveolin-1 expression controls satellite cell activation during muscle repair. FASEB J. 2005; 19: 237-9.
11. Way M, Parton RG. M-caveolin, a muscle-specific caveolin-related protein. FEBS Lett. 1996; 378: 108-12.
12. Tang Z, Scherer PE, Okamoto T, et al. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem. 1996; 271: 2255-61.
13. Fanzani A, Musarò A, Stoppani E, et al. Hypertrophy and atrophy inversely regulate Caveolin-3 expression in myoblasts. Biochem Biophys Res Commun. 2007; 357: 314-8.
14. Hnasko R, Lisanti MP. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol. Interv. 2003; 3: 445-64.
15. Cohen AW, Hnasko R, Schubert W, et al. Role of caveolae and caveolins in health and disease. Physiol Rev. 2004; 84: 1341-79.
16. Woodman SE, Sotgia F, Galbiati F, et al. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology. 2004; 62: 538-43.
17. Gazzerro E, Sotgia F, Bruno C, et al. Caveolinopathies: from the biology of caveolin-3 to human diseases. Eur J Hum Genet. 2010; 18: 137-45.
18. Barr FG. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma. Cancer Res. 1999; 59: 1711s-5s.
19. Merlino G, Helman LJ. Rhabdomyosarcoma-working out the pathways. Oncogene. 1999; 18: 5340-8.
20. De Giovanni C, Landuzzi L, Nicoletti G, et al. Molecular and cellular biology of rhabdomyosarcoma. Future Oncol. 2009; 5: 1449-75.
21. Tonin PN, Scrable H, Shimada H, et al. Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res. 1991; 51: 5100-6.
22. Fine SW, Lisanti MP, Argani P, et al. Caveolin-3 is a sensitive and specific marker for rhabdomyosarcoma. Appl Immunohistochem Mol Morphol. 2005; 13: 231-6.
23. Rossi S, Poliani PL, Cominelli M, et al. Caveolin 1 is a marker of poor differentiation in Rhabdomyosarcoma. Eur J Cancer. 2011; 47: 561-72.
24. Scherer PE, Lewis RY, Volonte D, et al. Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complexin vivo. J Biol Chem. 1997; 272: 29337-46.
25. Fra AM, Williamson E, Simons K, et al. De novoformation of caveolae in lymphocytes by expression of VIP21-caveolin. Proc Natl Acad Sci USA. 1995; 92: 8655-9.
26. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001; 293: 2449-52.
27. Galbiati F, Engelman JA, Volonte D, et al. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J Biol Chem. 2001; 276: 21425-33.
28. Hagiwara Y, Sasaoka T, Araishi K, et al. Caveolin-3 deficiency causes muscle degeneration in mice. Hum Mol Genet. 2000; 9: 3047-54.
29. Hill MM, Bastiani M, Luetterforst R, et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell. 2008; 132: 113-24.
30. Liu L, Pilch PF. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J Biol Chem. 2008; 283: 4314-22.
31. Pelkmans L, Bürli T, Zerial M, et al. Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic. Cell. 2004; 118: 767-80.
32. Kurzchalia TV, Dupree P, Parton RG, et al. VIP21, a 21-kDa membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. J Cell Biol. 1992; 118: 1003-14.
33. Glenney JR Jr, Soppet D. Sequence and expression of caveolin, a protein component ofcaveolaeplasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc Natl Acad Sci USA. 1992; 89: 10517-21.
34. Schlegel A, Lisanti MP. A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 carboxy-terminal domain mediate membrane binding and oligomer/oligomer interactionsin vivo. J Biol Chem. 2000; 275: 21605-17.
35. Liu P, Rudick M, Anderson RG. Multiple functions of caveolin-1. J Biol Chem. 2002; 277: 41295-8.
36. Li WP, Liu P, Pilcher BK, et al. Cell-specific targeting of caveolin-1 tocaveolae, secretory vesicles, cytoplasm or mitochondria. J Cell Sci. 2001; 114: 1397-408.
37. Okamoto T, Schlegel A, Scherer PE, et al. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem. 1998; 273: 5419-22.
38. Murata M, Peränen J, Schreiner R, et al. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci USA. 1995; 92: 10339-43.
39. Mercier I, Jasmin JF, Pavlides S, et al. Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders. Lab Invest. 2009; 89: 614-23.
40. Razani B, Combs TP, Wang XB, et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem. 2002; 277: 8635-47.
41. Cohen AW, Razani B, Wang XB, et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol. 2003; 285: 222-35.
42. Zhao YY, Liu Y, Stan RV, et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA. 2002; 99: 11375-80.
43. Jasmin JF, Mercier I, Hnasko R, et al. Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. Cardiovasc Res. 2004; 63: 747-55.
44. Cohen AW, Park DS, Woodman SE, et al. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol. 2003; 284: 457-74.
45. Sonveaux P, Martinive P, DeWever J, et al. Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res. 2004; 95: 154-61.
46. Jasmin JF, Malhotra S, Singh Dhallu M, et al. Caveolin-1 deficiency increases cerebral ischemic injury. Circ Res. 2007; 100: 721-9.
47. Patel HH, Tsutsumi YM, Head BP, et al. Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1. FASEB J. 2007; 21: 1565-74.
48. Razani B, Wang XB, Engelman JA, et al. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol. 2002; 22: 2329-44.
49. Schubert W, Sotgia F, Cohen AW, et al. Caveolin-1(-/-)- and caveolin-2(-/-)-deficient mice both display numerous skeletal muscle abnormalities, with tubular aggregate formation. Am J Pathol. 2007; 170: 316-33.
50. Woodman SE, Park DS, Cohen AW, et al. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem. 2002; 277: 38988-97.
51. Capozza F, Combs TP, Cohen AW, et al. Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle. Am J Physiol Cell Physiol. 2005; 288: 1317-31.
52. Engelman JA, Zhang XL, Lisanti MP. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett. 1998; 436: 403-10.
53. Galbiati F, Volonte D, Engelman JA, et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 1998; 17: 6633-48.
54. Capozza F, Williams TM, Schubert W, et al. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumour formation. Am J Pathol. 2003; 162: 2029-39.
55. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. 2001; 276: 38121-38.
56. Galbiati F, Volonte D, Liu J, et al. Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrestviaa p53/p21(WAF1/Cip1)-dependent mechanism. Mol Biol Cell 2001; 12: 2229-44.
57. Engelman JA, Wycoff CC, Yasuhara S, et al. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem. 1997; 272: 16374-81.
58. Lee SW, Reimer CL, Oh P, et al. Tumour cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 1998; 16: 1391-7.
59. Engelman JA, Chu C, Lin A, et al. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascadein vivo. A role for the caveolin-scaffolding domain. FEBS Lett. 1998; 428: 205-11.
60. Wiechen K, Diatchenko L, Agoulnik A, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumour suppressor gene. Am J Pathol. 2001; 159: 1635-43.
61. Racine C, Belanger M, Hirabayashi H, et al. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun. 1999; 255: 580-6.
62. Bonuccelli G, Casimiro MC, Sotgia F, et al. Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. Am J Pathol. 2009; 174: 1650-62.
63. Engelman JA, Lee RJ, Karnezis A, et al. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expressionin vitroandin vivo. Implications for mammary tumorigenesis. J Biol Chem. 1998; 273: 20448-55.
64. Sloan EK, Stanley KL, Anderson RL. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene. 2004; 23: 7893-7.
65. Wiechen K, Sers C, Agoulnik A, et al. Down-regulation of caveolin-1, a candidate tumour suppressor gene, in sarcomas. Am J Pathol. 2001; 158: 833-9.
66. Koleske AJ, Baltimore D, Lisanti MP. Reduction of caveolin andcaveolaein oncogenically transformed cells. Proc Natl Acad Sci USA. 1995; 92: 1381-5.
67. Patlolla JM, Swamy MV, Raju J, et al. Overespression of caveolin-1 in experimental colon adenocarcinoma and human colon cancer cell lines. Oncol Rep. 2004; 11: 957-63.
68. Rajjayabun PH, Garg S, Durkan GC, et al. Caveolin-1 expression is associated with high-grade bladder cancer. Urology. 2001; 58: 811-4.
69. Ando T, Ishiguro H, Kimura M, et al. The overexpression of caveolin-1 and caveolin-2 correlates with poor prognosis and tumour progression in esophageal squamous cell carcinoma. Oncol Rep. 2007; 18: 601-9.
70. Yang G, Truong LD, Wheeler TM, et al. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 1999; 59: 5719-23.
71. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol. 2005; 288: 494-506.
72. Burgermeister E, Liscovitch M, Röcken C, et al. Caveats of caveolin-1 in cancer progression. Cancer Lett. 2008; 268: 187-201.
73. Goetz JG, Lajoie P, Wiseman SM, et al. Caveolin-1 in tumour progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008; 27: 715-35.
74. Quest AF, Gutierrez-Pajares JL, Torres VA. Caveolin-1: an ambiguous partner in cell signalling and cancer. J Cell Mol Med. 2008; 12: 1130-50.
75. Lee H, Park DS, Razani B, et al. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1(-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol. 2002; 161: 1357-69.
76. Park DS, Lee H, Frank PG, et al. Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation and hyperactivation of the Jak-2/STAT5a signaling cascade. Mol Biol Cell. 2002; 13: 3416-30.
77. Williams TM, Cheung MW, Park DS, et al. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumour-prone transgenic mice. Mol Biol Cell. 2003; 14: 1027-42.
78. Williams TM, Medina F, Badano I, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasisin vivorole of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem. 2004; 279: 51630-46.
79. Williams TM, Lee H, Cheung MW, et al. Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene induced tumorigenesis: role of INK4a/CAV-1 in mammary epithelial cell hyperplasia. J Biol Chem. 2004; 279: 24745-56.
80. Williams TM, Hassan GS, Li J, et al. Caveolin-1 promotes tumour progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumour development in tramp mice. J Biol Chem. 2005; 280: 25134-45.
81. Nestl A, Von Stein OD, Zatloukal K, et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumours. Cancer Res. 2001; 61: 1569-77.
82. Ravid D, Maor S, Werner H, et al. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene. 2005; 24: 1338-47.
83. Belanger MM, Roussel E, Couet J. Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs. 2003; 14: 281-7.
84. Ravid D, Maor S, Werner H, et al. Caveolin-1 inhibits anoikis and promotes survival signaling in cancer cells. Advances in Enzyme Regulation. 2006; 46: 163-75.
85. Hayashi K, Matsuda S, Machida K, et al. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res. 2001; 61: 2361-4.
86. Han SE, Park KH, Lee G, et al. Mutation and aberrant expression of Caveolin-1 in human oral squamous cell carcinomas and oral cancer cell lines. Int J Oncol. 2004; 24: 435-40.
87. Lee H, Volonte D, Galbiati F, et al. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14)in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol. 2000; 14: 1750-75.
88. Schlegel A, Arvan P, Lisanti MP. Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. J Biol Chem. 2001; 276: 4398-408.
89. Cooper RN, Tajbakhsh S, Mouly V, et al. In vivosatellite cell activationviaMyf5 and MyoD in regenerating mouse skeletal muscle. J Cell Sci. 1999; 112: 2895-901.
90. Winchester PK, Davis ME, Alway SE, et al. Satellite cell activation in the stretch-enlarged anterior latissimus dorsi muscle of the adult quail. Am J Physiol. 1991; 260: 206-12.
91. Snow MH. Satellite cell response in rat soleus muscle undergoing hypertrophy due to surgical ablation of synergists. Anat Rec. 1990; 227: 437-46.
92. Song KS, Scherer PE, Tang Z, et al. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem. 1996; 271: 15160-5.
93. Sotgia F, Lee JK, Das K, et al. Caveolin-3 directly interacts with the carboxy-terminal tail of beta-dystroglycan. Identification of a central WW-like domain within caveolin family members. J Biol Chem. 2000; 275: 38048-58.
94. Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet. 1998; 18: 365-8.
95. Sunada Y, Ohi H, Hase A, et al. Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity. Hum Mol Genet. 2001; 10: 173-8.
96. Nixon SJ, Wegner J, Ferguson C, et al. Zebrafish as a model for caveolin-associated muscle disease; caveolin-3 is required for myofibril organization and muscle cell patterning. Hum Mol Genet. 2005; 14: 1727-43.
97. Stoppani E, Rossi S, Meacci E, et al. Point mutated caveolin-3 form (P104L) impairs myoblast differentiationviaAkt and p38 signalling reduction, leading to an immature cell signature. Biochim Biophys Acta. 2011; 1812: 468-79.
98. Vaghy PL, Fang J, Wu W, et al. Increased caveolin-3 levels in mdx mouse muscles. FEBS Lett. 1998; 431: 125-7.
99. Repetto S, Bado M, Broda P, et al. Increased number of caveolae and caveolin-3 overexpression in Duchenne muscular dystrophy. Biochem Biophys Res Commun. 1999; 261: 547-50.
100. Galbiati F, Volonte D, Chu JB, et al. Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype. Proc Natl Acad Sci USA. 2000; 97: 9689-94.
101. Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat Rev. 2004; 30: 269-80.
102. Ognjanovic S, Linabery AM, Charbonneau B, et al. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer. 2009; 115: 4218-26.
103. Berkes CA, Tapscott SJ. MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol. 2005; 16: 585-95.
104. Buckingham M, Bajard L, Chang T, et al. The formation of skeletal muscle: from somite to limb. J Anat. 2003; 202: 59-68.
105. Buckingham M, Montarras D. Skeletal muscle stem cells. Curr Opin Genet Dev. 2008; 18: 330-6.
106. Bergstrom DA, Tapscott SJ. Molecular distinction between specification and differentiation in the myogenic basic helix-loop-helix transcription factor family. Mol Cell Biol. 2001; 21: 2404-12.
107. Morotti RA, Nicol KK, Parham DM, et al. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol. 2006; 30: 962-8.
108. Tsokos M, Webber BL, Parham DM, et al. Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med. 1992; 116: 847-55.
109. Koufos A, Hansen MF, Copeland NG, et al. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature. 1985; 316: 330-4.
110. Scrable HJ, Cavenee W, Ghavimi F, et al. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci USA. 1989; 86: 7480-4.
111. Scrable HJ, Witte DP, Lampkin BC, et al. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature. 1987; 329: 645-7.
112. Loh WE Jr, Scrable HJ, Livanos E, et al. Human chromosome 11 contains two different growth suppressor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA. 1992; 89: 1755-9.
113. Anderson J, Gordon A, McManus A, et al. Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia. 1999; 1: 340-8.
114. Hao Y, Crenshaw T, Moulton T, et al. Tumour-suppressor activity of H19 RNA. Nature. 1993; 365: 764-7.
115. Matsuoka S, Thompson JS, Edwards MC, et al. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA. 1996; 93: 3026-30.
116. Schwienbacher C, Sabbioni S, Campi M, et al. Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumour samples. Proc Natl Acad Sci USA. 1998; 95: 3873-8.
117. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest. 1994; 94: 445-8.
118. Koi M, Johnson LA, Kalikin LM, et al. Tumour cell growth arrest caused by subchromosomal transferable DNA fragments from chromosome 11. Science. 1993; 260: 361-4.
119. Hoovers JM, Kalikin LM, Johnson LA, et al. Multiple genetic loci within 11p15 defined by Beckwith-Wiedemann syndrome rearrangement breakpoints and subchromosomal transferable fragments. Proc Natl Acad Sci USA. 1995; 92: 12456-60.
120. Bridge JA, Liu J, Weibolt V, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescencein situhybridization: an intergroup rhabdomyosarcoma study. Genes Chromosomes Cancer. 2000; 27: 337-44.
121. Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem. 2000; 275: 28341-4.
122. Stratton MR, Fisher C, Gusterson BA, et al. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 1989; 49: 6324-7.
123. Wilke W, Maillet M, Robinson R. H-ras-1 point mutations in soft tissue sarcomas. Mod Pathol. 1993; 6: 129-32.
124. Yoo J, Robinson RA. H-ras and K-ras mutations in soft tissue sarcoma: comparative studies of sarcomas from Korean and American patients. Cancer. 1999; 86: 58-63.
125. Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol. 1997; 19: 483-91.
126. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993; 3: 113-7.
127. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993; 5: 230-5.
128. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994; 54: 2869-72.
129. Davis RJ, Barr FG. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA. 1997; 94: 8047-51.
130. Del Peso L, Gonzalez VM, Hernandez R, et al. Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene. 1999; 18: 7328-33.
131. Fredericks WJ, Galili N, Mukhopadhyay S, et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol. 1995; 15: 1522-35.
132. Bennicelli JL, Edwards RH, Barr FG. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA. 1996; 93: 5455-9.
133. Bennicelli JL, Advani S, Schafer BW, et al. PAX3 and PAX7 exhibit conservedcis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene. 1999; 18: 4348-56.
134. Scheidler S, Fredericks WJ, Rauscher FJ 3rd, et al. The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc Natl Acad Sci USA. 1996; 93: 9805-9.
135. Lam PY, Sublett JE, Hollenbach AD, et al. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol Cell Biol. 1999; 19: 594-601.
136. Anderson J, Ramsay A, Gould S, et al. Pax3-fkhr induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol. 2001; 159: 1089-96.
137. Bernasconi M, Remppis A, Fredericks WJ, et al. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA. 1996; 93: 13164-9.
138. Margue CM, Bernasconi M, Barr FG, et al. Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene. 2000; 19: 2921-9.
139. Epstein JA, Lam P, Jepeal L, et al. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem. 1995; 270: 11719-22.
140. Anderson MJ, Shelton GD, Cavenee WK, et al. Embryonic expression of the tumour associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci USA. 2001; 98: 1589-94.
141. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250: 1233-8.
142. Felix CA, Kappel CC, Mitsudomi T, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 1992; 52: 2243-7.
143. Diller L, Sexsmith E, Gottlieb A, et al. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest. 1995; 95: 1606-11.
144. Taylor AC, Shu L, Danks MK, et al. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumours and cell lines. Med Pediatr Oncol. 2000; 35: 96-103.
145. Lindor NM, McMaster ML, Lindor CJ, et al. Concise handbook of familial cancer susceptibility syndromes-second edition. J Natl Cancer Inst Monogr. 2008; 38: 1-93.
146. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA. 1997; 94: 701-6.
147. Sharp R, Recio JA, Jhappan C, et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med. 2002; 8: 1276-80.
148. Kim SY, Toretsky JA, Scher D, et al. The role of IGF-1R in pediatric malignancies. Oncologist. 2009; 14: 83-91.
149. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res. 2001; 11: 289-97.
150. Blandford MC, Barr FG, Lynch JC, et al. Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2006; 46: 329-38.
151. De Giovanni C, Landuzzi L, Frabetti F, et al. Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. Cancer Res. 1996; 56: 3898-901.
152. Ganti R, Skapek SX, Zhang J, et al. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol. 2006; 19: 1213-20.
153. Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 2008; 27: 6550-60.
154. Onisto M, Slongo ML, Gregnanin L, et al. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol. 2005; 27: 791-8.
155. Gee MF, Tsuchida R, Eichler-Jonsson C, et al. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene. 2005; 24: 8025-37.
156. Wang W, Slevin M, Kumar S, et al. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts. Int J Oncol. 2005; 27: 1087-96.
157. Taylor JG 6th, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009; 119: 3395-407.
158. Ebauer M, Wachtel M, Niggli FK, et al. Comparative expression profiling identifies anin vivotarget gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene. 2007; 26: 7267-81.
159. Nanni P, Nicoletti G, Palladini A, et al. Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. Mol Cancer Ther. 2009; 8: 754-61.
160. Taulli R, Scuoppo C, Bersani F, et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res. 2006; 66: 4742-9.
161. Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA. 1999; 96: 13264-9.
162. Dias P, Kumar P, Marsden HB, et al. N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS. Int J Cancer. 1990; 45: 593-6.
163. Driman D, Thorner PS, Greenberg ML, et al. MYCN gene amplification in rhabdomyosarcoma. Cancer. 1994; 73: 2231-7.
164. Marampon F, Ciccarelli C, Zani BM. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumours. Mol Cancer. 2006; 5: 31.
165. Keleti J, Quezado MM, Abaza MM, et al. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol. 1996; 149: 143-51.
166. Iolascon A, Faienza MF, Coppola B, et al. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer. 1996; 15: 217-22.
167. Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science. 1993; 259: 1450-3.
168. Puri PL, Wu Z, Zhang P, et al. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev. 2000; 14: 574-84.
169. Puri PL, Sartorelli V. Regulation of muscle regulatory factors by DNA-binding, interacting proteins, and post-transcriptional modifications. J Cell Physiol. 2000; 185: 155-73.
170. Yang Z, MacQuarrie KL, Analau E, et al. MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. Genes Dev. 2009; 23: 694-707.
171. Davicioni E, Finckenstein FG, Shahbazian V, et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 2006; 66: 6936-46.
172. Graf Finckenstein F, Shahbazian V, Davicioni E, et al. PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis. Oncogene. 2008; 27: 2004-14.
173. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356: 215-21.
174. Jacks T, Remington L, Williams BO, et al. Tumour spectrum analysis in p53-mutant mice. Curr Biol. 1994; 4: 1-7.
175. Fleischmann A, Jochum W, Eferl R, et al. Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumour suppression by the Fos protooncogene. Cancer Cell. 2003; 4: 477-82.
176. Nanni P, Nicoletti G, De Giovanni C, et al. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res. 2003; 63: 2728-32.
177. Tsumura H, Yoshida T, Saito H, et al. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene. 2006; 25: 7673-9.
178. Keller C, Arenkiel BR, Coffin CM, et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 2004; 18: 2614-26.
179. Hahn H, Wojnowski L, Zimmer AM, et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med. 1998; 4: 619-22.
180. Chamberlain JS, Metzger J, Reyes M, et al. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 2007; 21: 2195-204.
181. Langenau DM, Keefe MD, Storer NY, et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 2007; 21: 1382-95.
182. Ferrari A, Bisogno G, Macaluso A, et al. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer. 2007; 109: 1406-12.
183. Kratz CP, Steinemann D, Niemeyer CM, et al. Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome. Hum Mol Genet. 2007; 16: 374-9.
184. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med. 2004; 6: 530-9.
185. Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 2007; 99: 24-31.
186. Hanks S, Coleman K, Summersgill B, et al. Comparative genomic hybridization and BUB1B mutation analyses in childhood cancers associated with mosaic variegated aneuploidy syndrome. Cancer Lett. 2006; 239: 234-8.
187. Kratz CP, Holter S, Etzler J, et al. Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J Med Genet. 2009; 46: 418-20.
188. Charytonowicz E, Cordon-Cardo C, Matushansky I, et al. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett. 2009; 279: 126-36.
189. Mercado GE, Barr FG. Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances. Curr Mol Med. 2007; 7: 47-61.
190. Merlino G, Khanna C. Fishing for the origins of cancer. Genes Dev. 2007; 21: 1275-9.
191. Linardic CM, Downie DL, Qualman S, et al. Genetic modeling of human rhabdomyosarcoma. Cancer Res. 2005; 65: 4490-5.
192. Ren YX, Finckenstein FG, Abdueva DA, et al. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res. 2008; 68: 6587-97.
193. Keller C, Capecchi MR. New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. Cancer Res. 2005; 65: 7530-2.
194. Biederer CH, Ries SJ, Moser M, et al. The basic helix-loop-helix transcription factors myogenin and Id2 mediate specific induction of caveolin-3 gene expression during embryonic development. J Biol Chem. 2000; 275: 26245-51.
195. Martìnez-Moreno M, Martìnez-Ruiz A, Alvarez-Barrientos A, et al. Nitric oxide down-regulates caveolin-3 levels through the interaction with myogenin, its transcription factor. J Biol Chem. 2007; 282: 23044-54.
196. Chardin P, Yeramian P, Madaule P, et al. N-ras gene activation in the RD human rhabdomyosarcoma cell line. Int J Cancer. 1985; 35: 647-52.
197. Sowa G, Pypaert M, Fulton D, et al. The phosphorylation of caveolin-2 on serines 23 and 36 modulates caveolin-1-dependent caveolae formation. Proc Natl Acad Sci USA. 2003; 100: 6511-6.
198. Sowa G, Xie L, Xu L, et al. Serine 23 and 36 phosphorylation of caveolin-2 is differentially regulated by targeting to lipid raft/caveolae and in mitotic endothelial cells. Biochemistry. 2008; 47: 101-11.
199. Volonte D, Zhang K, Lisanti MP, et al. Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts. Mol Biol Cell. 2002; 13: 2502-17.
200. Dasari A, Bartholomew JN, Volonte D, et al. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res. 2006; 66: 10805-14.
201. Bartholomew JN, Galbiati F. Mapping of oxidative stress response elements of the caveolin-1 promoter. Methods Mol Biol. 2010; 594: 409-23.
202. Bartholomew JN, Volonte D, Galbiati F. Caveolin-1 regulates the antagonistic pleiotropic properties of cellular senescence through a novel Mdm2/p53-mediated pathway. Cancer Res. 2009; 69: 2878-86.
203. Volonte D, Galbiati F. Inhibition of thioredoxin reductase 1 by caveolin 1 promotes stress-induced premature senescence. EMBO Rep. 2009; 10: 1334-40.
204. Panetta D, Biedi C, Repetto S, et al. IGF-I regulates caveolin 1 and IRS1 interaction in caveolae. Biochem Biophys Res Commun. 2004; 316: 240-3.
205. Salani B, Briatore L, Garibaldi S, et al. Caveolin-1 down regulation inhibits IGF-IR signal transduction in H9C2 rat cardio myoblasts. Endocrinology. 2008; 149: 461-5.
206. Chen J, Capozza F, Wu A, et al. Regulation of insulin receptor substrate-1 expression levels by caveolin-1. J Cell Physiol. 2008; 217: 281-9.
207. Salani B, Passalacqua M, Maffioli S, et al. IGF-IR internalizes with Caveolin-1 and PTRF/Cavin in Hacat cells. PLoS One. 2010; 5: 14157.
208. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem. 1997; 272: 30429-38.
209. Yamamoto M, Toya Y, Jensen RA, et al. Caveolin is an inhibitor of platelet-derived growth factor receptor signaling. Exp Cell Res. 1999; 247: 380-8.
210. Labrecque L, Royal I, Surprenant DS, et al. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell. 2003; 14: 334-47.
211. Li S, Couet J, Lisanti MP. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem. 1996; 271: 29182-90.
212. Schaaf G, Hamdi M, Zwijnenburg D, et al. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumours carrying a mutated RAS gene. Cancer Res. 2010; 70: 762-71.
213. Razani B, Zhang XL, Bitzer M, et al. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem. 2001; 276: 6727-38.
214. Bouché M, Canipari R, Melchionna R, et al. TGF-beta autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells. FASEB J. 2000; 14: 1147-58.
215. Ricaud S, Vernus B, Duclos M, et al. Inhibition of autocrine secretion of myostatin enhances terminal differentiation in human rhabdomyosarcoma cells. Oncogene. 2003; 22: 8221-32.
216. Langley B, Thomas M, McFarlane C, et al. Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway. Oncogene. 2004; 23: 524-34.
217. Yang Z, Zhang J, Cong H, et al. A retrovirus-based system to stably silence GDF-8 expression and enhance myogenic differentiation in human rhabdomyosarcoma cells. J Gene Med. 2008; 10: 825-33.
218. Rossi S, Stoppani E, Puri PL, et al. Differentiation of human rhabdomyosarcoma RD cells is regulated by reciprocal, functional interactions between myostatin, p38 and extracellular regulated kinase signalling pathways. Eur J Cancer. 2011; 47: 1095-105.
219. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997; 390: 465-471.
220. Massagué J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000; 1: 169-78.
221. Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta. 2008; 1782: 197-228.
222. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425: 577-84.
223. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997; 387: 83-90.
224. Ohsawa Y, Hagiwara H, Nakatani M, et al. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J Clin Invest. 2006; 116: 2924-34.
225. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumours. J Clin Invest. 2002; 109: 863-7.
226. Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009; 7: 17.
227. Perrone L, Peluso G, Melone MA. RAGE recycles at the plasma membrane in S100B secretory vesicles and promotes Schwann cells morphological changes. J Cell Physiol. 2008; 217: 60-71.
228. Reddy MA, Li SL, Sahar S, et al. Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J Biol Chem. 2006; 281: 13685-93.
229. Riuzzi F, Sorci G, Donato R. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumour formationin vivo. J Biol Chem. 2006; 281: 8242-53.
230. Riuzzi F, Sorci G, Donato R. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumour growth. Am J Pathol. 2007; 171: 947-61.